Answers are grounded in this paper and cite their sources.
Mostafa Nakacha*, Jean-René Authelina, Carlo Corsinib & Giovanni Gianolaba Sanofi R&D, Vitry sur Seine, France; b F.P.S. Food and Pharma Systems Srl, Como, ItalySupplemental data for this article is available online at on the publisher’s website.CONTACT Mostafa Nakach mostafa.nakach@sanofi.com Sanofi R&D, 1, Impasse des ateliers, 94403, Vitry sur Seine, FranceAbstractJet milling is frequently used in pharmaceutical industry to achieve different objectives. It can be used as enabling technology to overcome poor water solubility linked to hydrophobic active of pharmaceutical ingredient (API) by reducing the particle size and therefore increasing the dissolution rate. Alternatively, jet milling can be used either to enhance blending efficiency of API with excipient in case of formulation at low dosage strength or to achieve the required particle size for inhalation therapy. In this study, development of commercial manufacturing process of sticky API and its industrialization are described. The methodology used is based on quality-by-design approach to deliver safe, effective and robust manufacturing process. The study showed that the specific energy is a key factor that drives particle size during jet milling and the scale-up from lab to industrial scale. After understanding the process, a design space was built where different zones such as operating point, operating space (where the product is compliant to specification despite variability of process parameters), and the knowledge space were outlined. Finally, an industrial installation was proposed to deliver product with high productivity yield, compliant with safety regulation, and cleanable in place.
No takes yet. Share an insight, caveat, or question.
Nakach et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: